Sanofi (SNY)
| Market Cap | 106.33B -22.3% |
| Revenue (ttm) | 54.85B +5.5% |
| Net Income | 9.17B +40.5% |
| EPS | 7.48 +43.6% |
| Shares Out | 2.44B |
| PE Ratio | 11.59 |
| Forward PE | 9.21 |
| Dividend | $1.60 (3.67%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,764,801 |
| Open | 43.90 |
| Previous Close | 43.63 |
| Day's Range | 43.49 - 44.14 |
| 52-Week Range | 43.34 - 59.17 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 61.50 (+41.06%) |
| Earnings Date | Apr 23, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 41.06% from the latest price.
News
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own se...
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030,...
P/E Ratio Insights for Sanofi
In the current session, Sanofi Inc. (NASDAQ: SNY) is trading at $43.87, after a 1.54% decrease. Over the past month, the stock fell by 9.80% , and in the past year, by 25.32% . With performance like ...
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug
(RTTNews) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19 -Influenza vacci...
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe...
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report
Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an amendment to its "Docum...
Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Docume...
Sino Biopharmaceutical (SBHMY) Strikes $1.53B Deal with Sanofi for Cancer Drug
Sino Biopharmaceutical (SBHMY) Strikes $1.53B Deal with Sanofi for Cancer Drug
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Sanofi's Rilzabrutinib Gets Orphan Drug Designation In Japan For IgG4-Related Disease
(RTTNews) - Sanofi (SNY, SAN.PA, SNYNF) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to Rilzabrutinib for IgG4-related disease (IgG4-RD...
Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease
(RTTNews) - Sanofi (SNY, SAN.PA) announced the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to rilzabrutinib, an oral, reversible covalent Bruton's tyrosine kina...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion fo...
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ta...
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 s...